This year hasn't been an easy one for Novavax (NASDAQ: NVAX) investors. After a series of stumbles culminating in its disastrous earnings report on Aug. 8, its shares are down by 60% so far in 2022. And with management slashing its full-year revenue guidance by roughly half, there isn't much hope for smoother sailing for at least a few quarters.
A more than 30% peak decline in the Nasdaq Composite is allowing investors to buy these phenomenal stocks at bargain-basement prices.
(Bloomberg) -- The selloff in Novavax Inc. shares deepened on Tuesday, to erase $17 billion in market value from last year’s record high, after the Covid-19 vaccine maker slashed its revenue guidance.Most Read from BloombergMusk Sells $6.9 Billion of Tesla to Avoid Twitter Fire SaleUK Plans for Blackouts in January in Emergency Energy PlanTrump Under Intense Legal Scrutiny After FBI Searches Mar-a-LagoRussia Is Scouring the Globe for Weapons to Use Against UkraineTrump Search Was Unprecedented,